

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby appoint:

☒ Practitioners at Customer Number: **52286** as my/our attorney(s) or agent(s) to prosecute the applications identified in the attached Table A, and to transact all business in the United States Patent and Trademark Office connected with said applications.

Address all telephone calls and correspondence to:

**Paul K. Legaard, Ph.D.
Pepper Hamilton LLP
400 Berwyn Park
899 Cassatt Road
Berwyn, PA 19312
Tel: 610.640.7859**


I am the:

☐ Applicant/Inventor.
☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Signature of Applicant or Assignee of Record

Respectfully submitted,
AstraZeneca AB

Date: 12 October 2007

By: 
Name: Anna-Lena Rosendahl
Title: Director IP Services

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT UNDER 37 CFR 3.73(b)

Applicant, AstraZeneca AB, a company created and existing under the laws of Sweden, states that it is:

☒ the assignee of the entire right, title, and interest of the patents/applications identified in Table A attached hereto.

The extent (by, percentage) of its ownership interest is **100%** in the patents/applications identified in Table A.

☒ a copy of the pertinent assignment from the inventor(s) of the patent applications identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Respectfully submitted,

AstraZeneca AB

Date: 12 October 2007

By: 
Name:
Title:

Anna-Lena Rosendahl
Director IP Services

Table A

Docket No.	Serial/Patent No. Filing/Issue Date	Inventor(s)	Examiner	Art Unit	Title
133087.14701 101431-IP US	10/599,824 10-11-2006	Cathy Dantzman	To Be Determined	To Be Determined	2-(ARYALKOXY)-1-PHENYLETHYLAMINE DERIVATIVES AS NK1 ANTAGONIST AND SEROTONIN REUPTAKE INHIBITORS
133087.16101 102638-1 US	11/622,596 01-12-2007	Carl-Gustav Sigfridsson	To Be Determined	To Be Determined	NOVEL CRYSTALLINE FORMS 1
133087.16201 102639-1 US	11/622,606 01-12-2007	Soren Andersen et al.	To Be Determined	To Be Determined	NOVEL CRYSTALLINE FORMS 2

ASSIGNMENT

Now, therefore, for good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, I/we

Cathy DANTZMAN of AstraZeneca Pharmaceuticals, P.O. Box 15437, Wilmington, Delaware 19850-5437, USA

hereafter referred to as ASSIGNOR (S),

Hereby sell(s), assign(s) and transfer(s) to ASSIGNEE **AstraZeneca AB**, a company created and existing under the laws of Sweden, having its Head Office at SE-151 85 Södertälje, Sweden, and the successors, assigns and legal representatives of the ASSIGNEE, the entire right, title and interest for the United States and its territorial possessions, and in all foreign countries, in and to the inventions and any and all improvements thereon which are the subject of an application entitled:

2- (ARYLALKOXY) -1-PHENYLETHYLAMINE DERIVATIVES AS NK1 ANTAGONIST AND SEROTONIN REUPTAKE INHIBITORS

And which is disclosed in:

- (a) ☐ U.S. patent application executed on even date herewith;
- (b) ☐ U.S. patent application executed on ____;
- (c) ☐ U.S. application no. ____ filed on ____;
- (d) ☒ International application no. PCT/SE2005/000499 filed on 6 April 2005.

And in and to the above application and any legal equivalent thereof in a foreign country, including the right to claim priority, and in and to any division, continuation or continuation-in-part, renewal or substitute thereof, and in and to all resulting Letters Patents or any reissue or reexamination thereof, to have and to hold the same to the full end of the term or terms for which any and all of said Letters Patent may be granted;

ASSIGNOR(S) authorize(s) and request(s) the Issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns;

ASSIGNOR(S) hereby covenant(s) that ASSIGNOR(S) has/have the full power to make this assignment, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment; and

Without further payment or compensation by the ASSIGNEE or its successors and assigns, ASSIGNOR(S) further covenant(s) and agree(s) to communicate to said ASSIGNEE or its representatives, agents, its successors or assigns, any facts relating to said invention or inventions including evidence for purposes of interference or other administrative or legal proceedings whenever requested; to testify in any interference, legal or administrative proceedings, whenever requested; to execute and deliver, on request, all lawful papers required to make any of the foregoing provisions effective; and to do everything possible to aid said ASSIGNEE, its successors or assigns and nominees to secure, obtain and enforce proper patent protection for said invention or inventions in this or any foreign country.

Any attorney of record is authorized and requested by the execution of this assignment to insert into this assignment any further information necessary for recordation of this document.

IN WITNESS WHEREOF, I have hereunto set my hand and seal on the date below written.

Cathy Dantzman
Cathy DANTZMAN
Signature of Assignor

8-11-2006
Date of Assignor's Signature

WITNESSED BY:

Elizabeth Ashton
Signature of Witness
Name of Witness Elizabeth Ashton
(Type or print clearly)

Frances Toukaldian
Signature of Witness
Name of Witness FRANCES TOUTKALDIAN
(Type or print clearly)

Additional signature pages attached: ☐ Yes ☒ No